Trials / Terminated
TerminatedNCT02048904
Use of Sitagliptin to Decrease Microalbuminuria
Clinical Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Urinary Albumin to Creatinine Ratio in Patients With Overt Kidney Disease
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 142 (actual)
- Sponsor
- University of Missouri-Columbia · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The people being asked to participate in this study have type 2 diabetes and abnormal levels of protein in their urine. This indicates that they are starting to develop diabetic kidney disease. The standard treatment for this is the use of one of two blood pressure medicines, either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). However, these medicines are not always completely effective in stopping/reversing the kidney disease. Some studies have previously suggested that another type of medicine, called sitagliptin, normal used to treat diabetes may also help prevent diabetic kidney disease from getting worse. This study is being performed to test the effectiveness of sitagliptin as compared to a placebo, along with a stable dose of an ACE inhibitor or ARB, to determine whether or not it will reduce protein levels in their urine. Protein levels in the urine are a marker of the severity of kidney disease.
Detailed description
The people being asked to participate in this study have type 2 diabetes and abnormal levels of protein in their urine. This indicates that they are starting to develop diabetic kidney disease. The standard treatment for this is the use of one of two blood pressure medicines, either an ACE inhibitor or ARB. However, these medicines are not always completely effective in stopping/reversing the kidney disease. Some studies have previously suggested that another type of medicine, called sitagliptin, normal used to treat diabetes may also help prevent diabetic kidney disease from getting worse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitagliptin | Sitagliptin 100 mg/day for 3 months |
| DRUG | Placebo | Placebo 1 pill/day for 3 months |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-06-01
- First posted
- 2014-01-29
- Last updated
- 2017-08-10
- Results posted
- 2017-08-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02048904. Inclusion in this directory is not an endorsement.